News related to Floxin (Ofloxacin) and/or conditions it is approved for
Aradigm Doses First Patient In Long-Term Phase 2 Study Of A Novel Inhaled Ciprofloxacin Formulation For The Management Of Respiratory Infections
Source: Respiratory / Asthma News From Medical News Today [2009.11.18]
Aradigm Corporation (OTCBB:ARDM) (the "Company") announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis. The randomized, double-blind, placebo-controlled trial will be conducted in Australia and New Zealand.
levofloxacin, Levaquin
Source: MedicineNet Legionnaire Disease and Pontiac Fever Specialty [2008.12.15]
Title: levofloxacin, Levaquin
Category: Medications
Created: 4/3/1999 1:39:00 PM
Last Editorial Review: 12/15/2008
ciprofloxacin, Cipro, Cipro XR, Proquin XR
Source: MedicineNet Bioterrorism Specialty [2008.07.12]
Title: ciprofloxacin, Cipro, Cipro XR, Proquin XR
Category: Medications
Created: 12/31/1997
Last Editorial Review: 7/12/2008
ciprofloxacin/dexamethasone-otic suspension, Ciprodex
Source: MedicineNet Ear Tubes Specialty [2005.03.02]
Title: ciprofloxacin/dexamethasone-otic suspension, Ciprodex
Category: Medications
Created: 3/2/2005
Last Editorial Review: 3/2/2005
Mpex Reports Positive Phase II Results With Aeroquin, Delivered By PARI Pharma's EFlow Technology
Source: Cystic Fibrosis News From Medical News Today [2009.09.15]
Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.
Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results With Aeroquin(R) (MP-376) Treatment In Cystic Fibrosis Patients
Source: Cystic Fibrosis News From Medical News Today [2009.09.11]
Mpex Pharmaceuticals, Inc. announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
|
